Table 1.

Study and sample characteristics of article selection

Author	Year	Country	Methodology	Perspective	Type of costs	Topic	Patient sample characteristics
							Cancer type	Cancer stage	Age	Time horizon
Ragnarson-Tennvall and Wilking [26]	1999	Sweden	Cost-effectiveness	Healthcare sector	Direct medical, direct non-medical	Palliation and chemotherapy comparison	Pancreatic cancer	-	71 (mean)	Overall survival
Pasquali et al. [27]	2002	Italy	Cost of illness	Payer	Direct medical	Costing	Pancreatic cancer	All stages	72.1 (mean)	5 years
Aristides et al. [28]	2003	UK	Cost-effectiveness	Payer	Direct medical	Chemotherapy regimens comparison	Pancreatic cancer	II, III and IV	61/62 (median)	18 months
Bachmann et al. [29]	2003	UK	Cost-effectiveness	Service provider	Direct medical	Costs, hospital volume and doctor specialization	Pancreatic cancer	-	-	1 year
Hjelmgren et al. [30]	2003	Sweden	Cost of illness	Healthcare sector	Direct medical, direct non-medical	Costing	Pancreatic cancer	All stages	66.4 (mean)	Overall survival
Heinrich et al. [31]	2005	Switzerland	Cost–benefit	Service provider	Direct medical	Diagnostics and management strategy	Pancreatic cancer	All stages	61 (median)	18 months
Müller-Nordhorn et al. [32]	2005	Germany	Cost of illness	Payer, healthcare sector, society	Direct medical, direct non-medical, indirect	Costing	Pancreatic cancer	All stages	62 (mean)	2.5 years
Ljungman et al. [33]	2011	Sweden	Cost-utility	Service provider	Direct medical	Surgery	Exocrine/ampullary pancreatic adenocarcinoma	All stages	68 (mean)	Overall survival
Tingstedt et al. [34]	2011	Sweden	Cost of illness	Society	Direct medical, indirect	Costing	Pancreatic cancer excluding endocrine cancer	All stages	74 (median)	Overall survival
Walczak et al. [35]	2012	Poland	Cost-utility (Markov model)	Patient, payer	Direct medical	Chemotherapy regimens comparison	Pancreatic neuroendocrine tumours	All stages	-	Overall survival
Ansari et al. [36]	2013	Sweden	Cost of illness	Society	Direct medical, indirect	Chemotherapy regimens comparison	Pancreatic ductal adenocarcinoma	All stages	69 (median)	3 years
Ljungman et al. [37]	2013	Sweden	Cost-utility	Service provider	Direct medical	Palliation regimens comparison	Exocrine/ampullary pancreatic adenocarcinoma	-	66/69 (mean)	Overall survival
Carrato et al. [38]	2015	Spain	Cost-utility (Markov model)	Payer	Direct medical	Chemotherapy regimens comparison	Pancreatic adenocarcinoma	IV	63 (median)	10 years
Cucchetti et al. [39]	2015	Italy	Cost-effectiveness (Markov model)	Service provider	Direct medical	Surgery timing	Non-functioning pancreatic endocrine tumours	All stages	52 (median)	Overall survival
Gharaibeh et al. [40]	2015	UK	Cost-effectiveness, cost-utility (Markov model)	Payer	Direct medical	Chemotherapy regimens comparison	Pancreatic adenocarcinoma	IV	63 (median)	Overall survival
Hanly et al. [41]	2015	EU, Iceland	Burden of disease	Society	Indirect	Productivity loss	Pancreatic cancer	All stages	< 65	1 year
Joergensen et al. [42]	2016	Denmark	Cost-effectiveness	Service provider	Direct medical	High risk population screening	Pancreatic cancer	-	49 (median)	8 years
Gurusamy et al. [43]	2017	UK	Cost-utility (decision tree model)	Payer	Direct medical	Chemotherapy regimens comparison	Pancreatic cancer	-	-	5 years
Aronsson et al. [44]	2018	Sweden	Cost-effectiveness (Markov model)	Service provider	Direct medical	Management strategies comparison	Branch duct intraductal papillary mucinous neoplasm	-	65 (mean)	35 years
Briggs et al. [45]	2018	UK	Cost of illness (simulation model)	Payer	Direct medical	Costing	Pancreatic cancer	-	-	1 year
Gharaibeh et al. [46]	2018	UK	Cost-effectiveness, cost-utility (Markov model)	Payer	Direct medical	Chemotherapy regimens comparison	Ductal pancreatic adenocarcinoma	IV	> 60	Overall survival
Lazzaro et al. [47]	2018	Italy	Cost-effectiveness (Markov model)	Payer	Direct medical	Chemotherapy regimens comparison	Pancreatic cancer	IV	62/63 (median)	4 years
Mujica-Mota et al. [48]	2018	UK	Cost-effectiveness (semi Markov model)	Payer	Direct medical	Chemotherapy regimens comparison	Pancreatic neuroendocrine tumours	-	60 (mean)	40 years
Ahola et al. [49]	2019	Finland	Cost of illness, cost–benefit	Service provider	Direct medical	Hospital volume and resections	Pancreatic cancer	-	67 (median)	90 days
Morelli et al. [50]	2019	Italy	Cost of illness	Service provider	Direct medical	Diagnostics in surveillance follow-up	Pancreatic cyst neoplasm	-	67 (mean)	6 years
Thronicke et al. [51]	2020	Germany	Cost-effectiveness	Service provider	Direct medical	Integrative therapy	Pancreatic cancer	IV	63.7/68.6 (mean)	Overall survival